# Transcripta Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/transcripta-bio

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.transcriptabio.com
- Total disclosed funding: $24M
- Latest round: Series A (Jul 22, 2026)
- Investors on record: 4

## About

Based in California, US, and founded in 2020 by co-founder and CEO Chris Moxham and Onno Faber, Transcripta Bio, Inc., a.k.a. Transcripta Bio operates as a biotechnology company that focuses on developing a drug-gene atlas that maps molecular structure and drug action to the whole cell transcriptome, revealing therapeutic candidates that rebalance gene expression to treat disease. In July 2026, Transcripta Bio, Inc. raised USD 24 million in series A funding from Mayo Clinic Ventures, Omnimed Capital, JAZZ Venture Partners, and BlueYard Capital.
The company leverages its screening platform and Conductor AI predictive model to discover and predict the effects of new drugs at the transcriptome scale to discover and qualify novel candidates. Transcripta Bio’s approach provides a view of genome-wide biological activity for drug hunters. In addition, the firm’s discovery engine maps molecular structure and drug action to the whole cell transcriptome.
The company will use the July 2026 funding to advance IND-enabling studies across its portfolio and support clinical preparation in its autism spectrum disorder (ASD) and Facioscapulohumeral Muscular Dystrophy (FSHD) programs

## Funding rounds

- Series A, Jul 22, 2026, $24M — Mayo Clinic Ventures, JAZZ Venture Partners, BlueYard Capital, Omnimed Capital

## Investors

- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series A
- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Series A
- BlueYard Capital (https://capitalatlas.ai/funds/blueyard-capital) — Series A
- Omnimed Capital (https://capitalatlas.ai/funds/omnimed-capital) — Series A